Thank you, Mr. Chair.
Thank you to the witnesses for coming here this morning and testifying. It's much appreciated.
I'll start with the biotech industry. With regard to intellectual property protection, we've heard the story before that if we increase that, we'll actually increase investment into Canada. But that hasn't statistically played out.
What's different in this case? Are you suggesting that you'll have significantly more investment in research and development from your representative companies because of this deal? What's going to trigger that? And how do we measure that?